YALEPIC® magnetic bead-based cfDNA extraction kits deliver high-recovery, high-purity isolation of 150–170 bp short fragments from plasma, serum, and urine — providing a rock-solid pre-analytical foundation for cancer early screening, ctDNA mutation detection, NGS library preparation, and MRD monitoring.
In the era of precision medicine, liquid biopsy has emerged as a transformative approach for non-invasive cancer screening, therapy monitoring, and recurrence surveillance. Unlike traditional tissue biopsy requiring invasive needle biopsy or surgical sampling, liquid biopsy only needs a peripheral blood draw or body fluid collection to capture circulating tumor DNA (ctDNA) — enabling earlier tumor signal detection with minimal patient burden.
ctDNA is just a small subset of total cfDNA (cell-free DNA). In healthy individuals, cfDNA concentration in peripheral blood is about 10–1,000 copies/mL. In early-stage cancer patients, ctDNA may account for as little as 0.01%–1% of total cfDNA. This means cfDNA extraction recovery and purity directly determine the lower limit of ctDNA detection sensitivity. Inefficient extraction causes short-fragment loss and masks rare tumor signals, leading to false negatives that undermine the value of advanced sequencing platforms.
Each challenge must be overcome to ensure faithful delivery of tumor-derived signals to downstream analysis.
cfDNA in blood is present at extremely low concentrations, with the biologically informative fragments concentrated around 150–170 bp. Conventional genomic DNA extraction methods optimized for long fragments (kilobase range) systematically lose short cfDNA species — depleting the very material carrying tumor-specific mutations.
Plasma is rich in proteins, bilirubin, hemoglobin, and lipids; urine has high urea and salt concentrations. Residual impurities strongly inhibit downstream enzymatic reactions, causing NGS library failure, qPCR amplification bias, and compromised mutation call rates.
cfDNA is highly susceptible to nuclease-mediated degradation once outside the body. The extraction workflow must be gentle and protective — harsh lysis conditions can damage already fragile short fragments, destroying the very signal researchers seek to capture.
💡 Key Takeaway
cfDNA extraction is not merely the first step in the liquid biopsy workflow — it is the foundation upon which the sensitivity and reliability of the entire detection system rests. A high-performance extraction kit must simultaneously achieve efficient short-fragment capture, thorough impurity removal, and preservation of nucleic acid integrity.
YALI BIOTECH offers three differentially optimized magnetic bead-based cfDNA extraction kits, precisely matched to sample type, input volume, and throughput requirements — covering the full cancer research spectrum from benchtop experiments to clinical-scale screening.
Key Features:
Key Features:
Key Features:
Agilent 2100 Bioanalyzer HS chip confirms clean cfDNA peaks with minimal background — consistently low residual impurities across kit lots.
Adjustable input volumes produce cfDNA yield with excellent linearity — accommodating diverse experimental requirements.
Zero enzyme inhibition in qPCR/NGS. Libraries exhibit high yield and clean profiles — direct NGS compatibility.
Lot-to-lot consistency validation confirms minimal inter-lot variability from YALI BIOTECH’s standardized manufacturing — meeting reproducibility standards for high-impact research publications and clinical diagnostic traceability.
Precision-optimized for the 150–170 bp core cfDNA fragment range. Even low-abundance tumor-specific nucleic acids are efficiently enriched — ensuring sensitivity for low-frequency ctDNA mutation detection.
Thorough removal of proteins, salts, and pigments. Zero enzyme inhibitor carryover. Seamlessly compatible with qPCR, NGS panels, and methylation sequencing.
Three kits covering 0.2–1 mL plasma, 1–5 mL multi-type fluids, and 1–20 mL urine. Manual and automated — the complete oncology workflow solution.
Standardized manufacturing delivers minimal lot-to-lot variation. Meets data quality standards for top-tier publications and clinical diagnostic traceability.
Simplified protocol — no phenol-chloroform, no complex equipment. Compatible with YALEPIC® Pure series and mainstream automated workstations.
Non-denaturing lysis and binding avoids secondary damage to fragile short fragments. Maximally preserves tumor cfDNA integrity for fragmentomics and methylation analysis.
High-sensitivity extraction captures rare mutation signals before lesions appear on imaging — enabling non-invasive early cancer risk detection.
Detection of EGFR, KRAS, BRAF and other driver mutations from cfDNA provides molecular basis for individualized treatment selection.
Serial cfDNA concentration tracking enables dynamic treatment response assessment — consistent extraction ensures cross-timepoint data comparability.
Post-operative MRD detection and resistance mutation tracking rely on high-sensitivity ctDNA analysis. Urinary cfDNA supports non-invasive urological follow-up.
Q: What is the difference between cfDNA and ctDNA?
cfDNA (cell-free DNA) is the total pool of circulating free DNA from both normal and tumor cells. ctDNA (circulating tumor DNA) is the tumor-derived subset carrying cancer-specific mutations. In practice, total cfDNA must first be extracted, after which ctDNA signals are detected downstream. The recovery and purity of cfDNA extraction therefore directly limits ctDNA detection sensitivity.
Q: Why is 150–170 bp short-fragment recovery so critical?
The biologically informative cfDNA fragments center around 150–170 bp (mononucleosomal length) — these are the primary carriers of tumor-specific mutation signals. Conventional extraction methods optimized for long fragments (kilobase scale) poorly adsorb short fragments, causing substantial signal loss. All YALEPIC® kits are deeply optimized for 150–170 bp fragment capture.
Q: What is the value of urinary cfDNA extraction?
Urinary cfDNA is uniquely valuable for non-invasive screening and post-operative follow-up of urological cancers (bladder, kidney, prostate). Urine collection is more convenient with higher patient compliance, and urological tumor-derived ctDNA may be preferentially enriched in urine. YALI BIOTECH’s urine-specific kit includes a stabilizer and custom impurity removal system to address high salt content and rapid degradation.
Q: Are YALEPIC® kits compatible with automated platforms?
Yes. Kit I is compatible with the YALEPIC® Pure 32 automated system. Kit II is compatible with YALEPIC® Pure 16L and mainstream fully automated nucleic acid extraction workstations — supporting both low-throughput routine extraction and high-throughput batch processing. Manual protocols are equally streamlined.
YALI BIOTECH is a high-tech enterprise integrating R&D, manufacturing, and sales, headquartered in Suzhou, China. Our portfolio spans sample preparation, nucleic acid extraction & purification, molecular detection enzyme reagents, cell biology, and oncology research — with hundreds of products serving the life sciences, in vitro diagnostics, biopharmaceutical, and health testing sectors worldwide.
Simple Life, Simple Research
✉ Request a Quote or Technical Consultation
Or explore the full YALEPIC® product catalog.
Production center: 4th floor, Building 9, Yangshan Science and Technology
Industrial Park,No. 8 Jinyan Road, Suzhou High-tech Zone
Marketing center: Pujiang High-tech Park, Minhang District, Shanghai
Copyright: 2026 YALI Biotech Co., Ltd.
Scan to follow us